1. Towards Early and More Specific Diagnosis of Prostate Cancer
Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time 
Jack A. Schalken 
European Urology Supplements 
Volume 8, Issue 3, Pages (January 2009)
DOI: /j.eursup
Copyright © 2008 European Association of Urology Terms and Conditions

2. Fig. 1
Percentage of men with positive biopsy versus prostate cancer gene 3 score range. The number of men in each group is shown in parentheses.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

3. Fig. 2
Receiver operating characteristic curves for serum prostate-specific antigen (PSA), prostate cancer gene 3 (PCA3) score, and the logistic regression model incorporating serum PSA, PCA3 score, diagnostic digital rectal examination result, and prostate gland volume. PSA=prostate-specific antigen; AUC=area under the curve; PCA3=prostate cancer gene 3; LR=logistic regression; TRUSVol=transrectal ultrasound volume; DRE=digital rectal examination.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

4. Fig. 3
Mean prostate cancer gene 3 scores for men with low-volume/low-grade prostate cancer (<0.5cc, Gleason 6) versus significant prostate cancer (>0.5cc, Gleason ≥7). Error bars represent the standard error of the mean. PCa=prostate cancer. Reprinted from The Journal of Urology, Vol. 179(5), Nakanishi H, Groskopf J, Fritsche HA, et al, PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance, Pages 1804–10, Copyright (2008), with permission from The American Urological Association.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions